Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 8/20 | 0.47 |
| ▸ | PRKCA | P17252 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5227568 | 0.95 | GRIN2B (0.45) | GRIN2BPRKCAMMP12MAPTNPC1 | |
| SCHEMBL5198832 | 0.93 | MAPK1 (0.42) | GRIN2BPRKCAMMP12MAPTRAB9A | |
| SCHEMBL5198409 | 0.93 | GRIN2B (0.43) | GRIN2BPRKCAMMP12MAPTALDH1A1 | |
| SCHEMBL5439046 | 0.91 | PRKCA (0.44) | GRIN2BPRKCAMMP12MAPTALDH1A1 | |
| SCHEMBL5219597 | 0.91 | PRKCA (0.38) | GRIN2BPRKCAMMP12MAPTNR1I2 | |
| SCHEMBL5216547 | 0.90 | ALDH1A1 (0.42) | GRIN2BPRKCAMMP12MAPTNPC1 | |
| SCHEMBL5196260 | 0.89 | GRIN2B (0.40) | GRIN2BPRKCAMMP12MAPTALDH1A1 | |
| SCHEMBL5217612 | 0.88 | SCN9A (0.41) | GRIN2BPRKCAMMP12ALDH1A1NR1I2 | |
| SCHEMBL5934915 | 0.88 | SCN7A (0.38) | GRIN2BPRKCAMMP12MAPTNR1I2 | |
| SCHEMBL5197877 | 0.88 | GRIN2B (0.42) | GRIN2BPRKCAMMP12MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | GENELABS, INC. | 2006-09-21 | — | — | US | claimed |
| EP-1844042-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2007-10-17 | — | — | EP | disclosed |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | GENELABS, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006076529-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | HAVCR2, ZC3HAV1, SARS1 | GRIN2B 1821/4885PRKCA 4500/4885MMP12 4114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.